Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-23T20:20:04.175Z Has data issue: false hasContentIssue false
  • English
  • Français

Causes for Treatment Delays in Dystonia and Hemifacial Spasm: A Canadian Survey

Published online by Cambridge University Press:  02 December 2014

Mandar Jog ,
Sylvain Chouinard ,
Doug Hobson ,
David Grimes ,
Robert Chen ,
Meetu Bhogal  and
Susan Simonyi
Mandar Jog*
Affiliation:
Movement Disorders Program, London Health Sciences Centre, University of Western Ontario, London
Sylvain Chouinard
Affiliation:
Department of Neurology, University of Montreal, Montreal, Quebec
Doug Hobson
Affiliation:
Department of Medicine, Section of Neurology, University of Manitoba, Winnipeg, Manitoba, Canada
David Grimes
Affiliation:
Department of Medicine, Division of Neurology, The Ottawa Hospital, Ottawa, Ontario
Robert Chen
Affiliation:
Toronto Western Research Institute and Division of Neurology, Department of Medicine, University of Toronto, Toronto
Meetu Bhogal
Affiliation:
Allergan Canada Inc., Markham
Susan Simonyi
Affiliation:
Allergan Canada Inc., Markham
*
London Health Science Centre, Movement Disorders Clinic, 339 Windermere Road, London, Ontario, N6A 5A5, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Dystonia must be accurately diagnosed so that treatment can be administered promptly. However, dystonia is a complex disorder, with variable presentation, which can delay diagnosis.

Methods:

Data were gathered by questionnaire from 866 patients with dystonia or hemifacial spasm (HFS) treated in 14 movement disorders centres in Canada injecting botulinum toxin, to better understand the path to diagnosis, wait times and obstacles to treatment.

Results:

Most participants were female (64.1%), mean age was 58 years, and patients consulted an average of 3.2 physicians before receiving a dystonia or HFS diagnosis. Many patients (34%) received other diagnoses before referral to a movement disorders clinic, most commonly “stress” (42.7%). A variety of treatments were often received without a diagnosis. The mean lag time between symptom onset and diagnosis was 5.4 years. After the decision to use botulinum toxin, patients waited a mean of 3.1 months before treatment. The most common diagnoses were cervical dystonia (51.6% of patients), HFS (20.0%) and blepharospasm (9.8%).

Conclusions:

Survey results show that diagnosis of dystonias or of HFS, and therefore, access to treatment, is delayed. An educational program for primary care physicians may be helpful to decrease the time to diagnosis and referral to a specialist centre for treatment.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 5 , September 2011 , pp. 704 - 711
Copyright
Copyright © The Canadian Journal of Neurological 2011

References

1.Geyer, HL, Bressman, SB.The diagnosis of dystonia. Lancet Neurol. 2006; 5(9):780–90.CrossRefGoogle ScholarPubMed
2.Auger, RG, Whisnant, JP.Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol. 1990; 47(11):1233–4.CrossRefGoogle ScholarPubMed
3.Claypool, DW, Duane, DD, Ilstrup, DM, Melton, LJ III. Epidemiology and outcome of cervical dystonia (spasmodic torticollis) in Rochester, Minnesota. Mov Disord. 1995; 10(5):608–14.CrossRefGoogle ScholarPubMed
4.Nakashima, K, Kusumi, M, Inoue, Y, Takahashi, K.Prevalence of focal dystonias in the western area of Tottori Prefecture in Japan. Mov Disord. 1995; 10(4):440–3.CrossRefGoogle ScholarPubMed
5.A prevalence study of primary dystonia in eight European countries. J Neurol. 2000; 247(10):787–92.CrossRefGoogle Scholar
6.Marras, C, Van den Eeden, SK, Fross, RD, et al.Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology. 2007; 69(7):676–80.CrossRefGoogle Scholar
7.Nutt, JG, Muenter, MD, Aronson, A, Kurland, LT, Melton, LJ III. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord. 1988; 3(3):188–94.CrossRefGoogle ScholarPubMed
8.Defazio, G, Livrea, P, De Salvia, R, et al.Prevalence of primary blepharospasm in a community of Puglia region, Southern Italy. Neurology. 2001; 56(11):1579–81.CrossRefGoogle Scholar
9.Cossu, G, Mereu, A, Deriu, M, et al.Prevalence of primary blepharospasm in Sardinia, Italy: a service-based survey. Mov Disord. 2006; 21(11):2005–8.CrossRefGoogle ScholarPubMed
10.Hallett, M.Blepharospasm: recent advances. Neurology. 2002; 59(9):1306–12.CrossRefGoogle ScholarPubMed
11.Jankovic, J, Tsui, J, Bergeron, C.Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007; 13(7):411–16.CrossRefGoogle ScholarPubMed
12.Jankovic, J.Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009; 8(9):844–56.CrossRefGoogle ScholarPubMed
13.Simpson, DM, Blitzer, A, Brashear, AM, et al.Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70(19):1699–706.CrossRefGoogle Scholar
14.Albanese, A.The clinical expression of primary dystonia. J Neurol. 2003; 250(10):1145–51.CrossRefGoogle ScholarPubMed
15.Abdo, WF, van de Warrenburg, BP, Burn, DJ, Quinn, NP, Bloem, BR.The clinical approach to movement disorders. Nat Rev Neurol. 2010; 6(1):29–37.CrossRefGoogle ScholarPubMed
16.Swope, D, Barbano, R.Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin. 2008; 26 Suppl 1:54–65.CrossRefGoogle ScholarPubMed
17.Kenney, C, Jankovic, J.Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008; 115(4):585–91.CrossRefGoogle ScholarPubMed
18.Hallett, M, Evinger, C, Jankovic, J, Stacy, M.Update on blepharospasm: report from the BEBRF InternationalWorkshop. Neurology. 2008; 71(16):1275–82.CrossRefGoogle Scholar
19.Albanese, A, Lalli, S.Is this dystonia? Mov Disord. 2009; 24(12):1725–31.CrossRefGoogle ScholarPubMed
20.Hilker, R, Schischniaschvili, M, Ghaemi, M, Jacobs, A, Rudolf, J.Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001; 71(2):193–9.CrossRefGoogle ScholarPubMed